Search research articles
Contact Us
Filters
Showing results (31-40 of 34) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 34 results.
Science Translational Medicine
|
July 15, 2026
A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease
Aarash Bordbar, Bernard Bloem, Colton Lloyd, et al.
American Journal of Obstetrics & Gynecology MFM
|
May 21, 2022
Prophylactic endovascular internal iliac balloon placement during cesarean hysterectomy for placenta accreta spectrum
Eve Overton, Whitney A Booker, Mirella Mourad, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 14, 2006
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist
Kimberly E Vanover, David M Weiner, Malath Makhay, et al.
Journal of Hematology & Oncology
|
July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 34) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 34 results.
Science Translational Medicine
|
July 15, 2026
A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease
Aarash Bordbar, Bernard Bloem, Colton Lloyd, et al.
American Journal of Obstetrics & Gynecology MFM
|
May 21, 2022
Prophylactic endovascular internal iliac balloon placement during cesarean hysterectomy for placenta accreta spectrum
Eve Overton, Whitney A Booker, Mirella Mourad, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 14, 2006
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist
Kimberly E Vanover, David M Weiner, Malath Makhay, et al.
Journal of Hematology & Oncology
|
July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Page
of 4